Anti-NTE antibody (ab81387)

Overview

• Product nameAnti-NTE antibody
  See all NTE primary antibodies
• Description
  Rabbit polyclonal to NTE
• Tested applicationsSuitable for: WB, IHC-P, IHC-Frmore details
• Species reactivity
  Reacts with: Zebrafish
  
• Immunogen

  Synthetic peptide, corresponding to C terminal amino acids 1323-1348 of Zebrafish NTE

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
• Storage bufferPreservative: 0.02% Sodium Azide, 0.01% Thimerosal (merthiolate)
  Constituents: 2.5% BSA, 0.45% Sodium chloride, 0.1% Dibasic monohydrogen sodium phosphate
• Concentration information loading...
• PurityImmunogen affinity purified
• ClonalityPolyclonal
• IsotypeIgG
• Research areas
  • Neuroscience
  • Neurology process
  • Neurodegenerative disease
  • Other

  • Signal Transduction
  • Metabolism
  • Lipid metabolism

  • Metabolism
  • Types of disease
  • Cancer

Associated products

• Compatible Secondaries
  • Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077)
  • Goat Anti-Rabbit IgG H&L (HRP) (ab205718)

Applications

Target

• FunctionPhospholipase B that deacylates intracellular phosphatidylcholine (PtdCho), generating glycerophosphocholine (GroPtdCho). This deacylation occurs at both sn-2 and sn-1 positions of PtdCho. Its specific chemical modification by certain organophosphorus (OP) compounds leads to distal axonopathy.
• Tissue specificityExpressed in brain, placenta, kidney, neuron and skeletal muscle.
• Involvement in diseaseDefects in PNPLA6 are the cause of spastic paraplegia autosomal recessive type 39 (SPG39) [MIM:612020]; also known as NTE-related motor neuron disorder (NTEMND). Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG39 is associated with a motor axonopathy affecting upper and lower limbs and resulting in progressive wasting of distal upper and lower extremity muscles.
• Sequence similaritiesBelongs to the NTE family.
  Contains 3 cyclic nucleotide-binding domains.
  Contains 1 patatin domain.
• Post-translational
  modificationsGlycosylated.
• Cellular localizationEndoplasmic reticulum membrane. Anchored to the cytoplasmic face of the endoplasmic reticulum by its amino-terminal transmembrane segment.

• Target information above from: UniProt accession Q8IY17 The UniProt Consortium
  The Universal Protein Resource (UniProt) in 2010
  Nucleic Acids Res. 38:D142-D148 (2010) .

  Information by UniProt
• Database links
  • Entrez Gene: 386860 Zebrafish
• Alternative names
  • EC 3.1.1.5 antibody
  • Neuropathy target esterase antibody
  • NTEMND antibody

  • Patatin like phospholipase domain containing 6 antibody
  • Patatin like phospholipase domain containing protein 6 antibody
  • Patatin-like phospholipase domain-containing protein 6 antibody
  • PLPL6_HUMAN antibody
  • Pnpla6 antibody
  • SPG39 antibody
  • sws antibody

  see all